|
목적 : To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) injection with or without pneumatic displacement for the submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD).
방법 : All patients were treated by anti-VEGF injection with initial three loading injection by month, followed by an as-needed reinjection. In case of combined treatment, expansive gas was additionally injected at baseline. The efficacy of the treatment was analyzed between anti-VEGF monotherapy group (67 eyes) and anti-VEGF with pneumatic displacement group (44 eyes). Mean change in best corrected visual acuity (BCVA), which was converted to the logarithm of the minimum angle of resolution (log MAR), and proportion of patients gaining more than 3 lines of BCVA from baseline at 12 months.
결과 : The size of submacular hemorrhage averaged 8.2 ± 5.8 disc areas. The mean duration of symptoms was 8.2 ± 5.2 days. At the 12 months after treatment, mean BCVA had improved significantly from 1.20 logMAR (20/316, Snellen equivalent) to 0.96 logMAR (20/182, Snellen equivalent) in the anti-VEGF monotherapy group (P=0.008), and also improved significantly from 1.18 logMAR (20/302, Snellen equivalent) to 0.94 logMAR (20/182, Snellen equivalent) in the combined treatment group (P = 0. 003).
결론 : Anti-VEGF injection with or without pneumatic displacement could be valuable treatment options for SMH secondary to nAMD. Combined treatment was more effective in achieving higher proportion of BCVA gaining ≥ 3 lines, in particular with typical nAMD patients than PCV patients.
|